Huagong ShineYouth Deep Dive: How a University Spin-off Scaled the Borneol Microcrystal Patch

On China's dissolving-microneedle map, Huagong ShineYouth (Shenzhen) Technology Co., Ltd. is a landmark 'university spin-off' case. Founded in September 2021 and incubated from the technology-transfer achievements of the China-Singapore International Joint Research Institute and South China University of Technology (SCUT), the company is a certified National High-Tech Enterprise and 'Little Giant' SME headquartered in Longhua, Shenzhen. Unlike platform OEMs, ShineYouth chose an integrated R&D–manufacturing–sales model from day one: it develops core technology and runs its own consumer brand simultaneously.

Its technical foundation can be summarised as the pioneering 'dual-penetration' mechanism. The first layer is physical micro-channelling: water-soluble microcrystals painlessly penetrate the stratum corneum on application, dissolve in interstitial fluid and release actives at the target site. The second is molecular penetration promotion: natural right-turn borneol opens further absorption pathways. Combined, actives absorption improves more than tenfold; the company discloses 6–8 hour transdermal delivery rates of 50%–90%, far above conventional topical application — directly addressing the industry's chronic pain point of 'great ingredients, poor absorption'.

Academic backing defines the company. It co-built the Joint Research Centre for Innovative Pharmaceutics and Soluble Microcrystal Skincare with SCUT, with core R&D led by Prof. Su Jianyu's team; granted patents include a thermo-responsive borneol-based fast-dissolving microneedle eye mask. To date the company holds 30+ core patents (including international filings) around microneedles and penetration materials, plus utility models and software copyrights — a complete IP network spanning materials, formats and processes.

On product, the 'borneol microcrystal patch' series differentiates across high-frequency scenarios — acne, brightening, anti-wrinkle and eye care — with hero SKUs such as the dual-effect acne patch and brightening acne patch. The acne patch quickly became a bestseller on Xiaohongshu (RED). Selling points of 'safe, painless, efficient, metered release' — external, non-invasive, no surgery or laser, more efficient than ordinary patches — built a trust threshold in high-sensitivity efficacy scenarios such as facial acne care.

Its industrialisation record is among the strongest of university spin-offs: an automated microcrystal line with annual capacity exceeding 100 million patches (scaled up rapidly from two 60-million-patch lines), terminal sales above RMB 300m a year, and Frost & Sullivan certification as the No.1 soluble microcrystal patch brand. The supply chain is unusually complete: upstream, a standardised camphor-borneol plantation base secures high-purity natural borneol; downstream, links to skincare manufacturing and retail channels. Raw-material self-sufficiency proved its anti-risk value amid recent supply chain volatility.

Within the industry landscape, ShineYouth and Zhongke Weimicron represent two routes: Weimicron excels as a 'platform + OEM' CRO/CMO/CDMO service provider, while ShineYouth runs a dual engine of 'own brand + technology output', building consumer mindshare with academic endorsement, hero SKUs and scale manufacturing. On the completeness of 'academic authority + hit operations + mass production', it is one of the most representative industrial cases in the microcrystal patch category.

Looking ahead, category competition will upgrade along three fronts: clinical and efficacy evidence systems supporting higher-order claims; cross-border patent layouts against Korean and Japanese peers; and format extension — from standard patches to thermo-responsive steam microneedles and eye masks. ShineYouth's borneol supply base and thermo-responsive fast-dissolving patents already seed these directions. For the industry at large, the speed at which university spin-offs industrialise is resetting the competitive bar: the future question is no longer 'who has microneedles' but 'who leads in delivery efficiency, evidence chains and scale economics'.

Related